A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108. [electronic resource]
Producer: 20090827Description: 728-35 p. digitalISSN:- 1029-2403
- Adult
- Aged
- Aged, 80 and over
- Angiogenesis Inhibitors -- administration & dosage
- Antibodies, Monoclonal -- administration & dosage
- Antibodies, Monoclonal, Humanized
- Bevacizumab
- Biomarkers -- analysis
- Disease-Free Survival
- Humans
- Lymphoma, Large B-Cell, Diffuse -- drug therapy
- Lymphoma, Mantle-Cell -- drug therapy
- Lymphoma, Non-Hodgkin -- drug therapy
- Male
- Middle Aged
- Receptors, Vascular Endothelial Growth Factor -- analysis
- Salvage Therapy -- methods
- Southwestern United States
- Vascular Cell Adhesion Molecule-1 -- blood
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.